首页 > 最新文献

Journal of hypertension. Supplement : official journal of the International Society of Hypertension最新文献

英文 中文
Achieving blood pressure goals: should angiotensin II receptor blockers become first-line treatment in hypertension? 实现降压目标:血管紧张素受体阻滞剂是否应成为高血压的一线治疗?
Michael Weber

The benefits of blood pressure control on the risks of major cardiovascular events are well established. In clinical trials conducted in patients with mild-to-moderate hypertension, the angiotensin II receptor blocker (ARB) telmisartan has been shown to provide reduction of blood pressure throughout the 24-h dosing interval. Clinical trials have also demonstrated that ARBs are effective agents in reducing the risk of cardiovascular mortality, stroke, heart failure and new-onset atrial fibrillation. Recently, the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) study established that telmisartan reduces morbidity and mortality in a broad cross-section of patients at high risk for heart and vascular events, to an extent similar to that of the angiotensin-converting enzyme inhibitor ramipril. In addition, ONTARGET demonstrated that telmisartan is somewhat better tolerated than ramipril. Attributes such as effective blood pressure lowering, tolerability and convincing outcomes data mean that ARBs satisfy the requirements for first-line antihypertensive agents.

控制血压对主要心血管事件风险的益处已得到充分证实。在对轻中度高血压患者进行的临床试验中,血管紧张素II受体阻滞剂(ARB)替米沙坦已被证明可以在24小时给药间隔内降低血压。临床试验也表明,arb是降低心血管死亡、中风、心力衰竭和新发心房颤动风险的有效药物。最近,正在进行的替米沙坦单独和联合雷米普利全球终点试验(ONTARGET)研究证实,替米沙坦在广泛的心脏和血管事件高风险患者中降低了发病率和死亡率,其程度与血管紧张素转换酶抑制剂雷米普利相似。此外,ONTARGET表明替米沙坦的耐受性比雷米普利更好。有效降压、耐受性和令人信服的结局数据等属性意味着arb满足一线降压药的要求。
{"title":"Achieving blood pressure goals: should angiotensin II receptor blockers become first-line treatment in hypertension?","authors":"Michael Weber","doi":"10.1097/01.hjh.0000357903.93951.73","DOIUrl":"https://doi.org/10.1097/01.hjh.0000357903.93951.73","url":null,"abstract":"<p><p>The benefits of blood pressure control on the risks of major cardiovascular events are well established. In clinical trials conducted in patients with mild-to-moderate hypertension, the angiotensin II receptor blocker (ARB) telmisartan has been shown to provide reduction of blood pressure throughout the 24-h dosing interval. Clinical trials have also demonstrated that ARBs are effective agents in reducing the risk of cardiovascular mortality, stroke, heart failure and new-onset atrial fibrillation. Recently, the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) study established that telmisartan reduces morbidity and mortality in a broad cross-section of patients at high risk for heart and vascular events, to an extent similar to that of the angiotensin-converting enzyme inhibitor ramipril. In addition, ONTARGET demonstrated that telmisartan is somewhat better tolerated than ramipril. Attributes such as effective blood pressure lowering, tolerability and convincing outcomes data mean that ARBs satisfy the requirements for first-line antihypertensive agents.</p>","PeriodicalId":16074,"journal":{"name":"Journal of hypertension. Supplement : official journal of the International Society of Hypertension","volume":"27 5","pages":"S9-14"},"PeriodicalIF":0.0,"publicationDate":"2009-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.hjh.0000357903.93951.73","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28294746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
Effects of angiotensin II receptor blockers on diabetic nephropathy. 血管紧张素受体阻滞剂对糖尿病肾病的影响。
Rigas Kalaitzidis, George L Bakris

Impaired kidney function increases the risk of cardiovascular morbidity and mortality. Coexistence of hypertension and type 2 diabetes increases the risk of kidney damage, hypertension being an independent risk factor for kidney disease progression. Angiotensin II, through its inflammatory, proliferative, and thrombotic effects, adversely affects renal perfusion and increases oxidative stress, thus playing a pivotal role in kidney disease progression. Angiotensin II receptor blockers (ARBs) and angiotensin-converting enzyme (ACE) inhibitors improve markers of kidney disease and slow kidney disease progression in diabetic and nondiabetic patients; this kidney protection may be in addition to their antihypertensive activity in those with advanced proteinuric nephropathy. Key beneficial effects of ARBs and ACE inhibitors throughout the kidney disease continuum are primarily explained by blood pressure lowering effects and partially by their direct blockade of angiotensin II. Recent studies have shown that telmisartan, an ARB with high lipophilicity and the longest half-life compared with other ARBs, provides benefits on markers of cardiovascular risk, that is, microalbuminuria and slowing of early-stage nephropathy.

肾功能受损会增加心血管疾病发病率和死亡率的风险。高血压和2型糖尿病的共存增加了肾脏损害的风险,高血压是肾脏疾病进展的独立危险因素。血管紧张素II通过其炎症、增殖和血栓形成作用,对肾脏灌注产生不利影响并增加氧化应激,因此在肾脏疾病进展中起关键作用。血管紧张素II受体阻滞剂(ARBs)和血管紧张素转换酶(ACE)抑制剂改善糖尿病和非糖尿病患者肾脏疾病标志物和减缓肾脏疾病进展;这种肾脏保护作用可能是对晚期蛋白尿肾病患者的抗高血压作用的补充。arb和ACE抑制剂在整个肾脏疾病连续体中的关键有益作用主要是通过降血压作用和部分通过直接阻断血管紧张素II来解释的。最近的研究表明,替米沙坦是一种与其他ARB相比具有高亲脂性和最长半衰期的ARB,对心血管风险标志物,即微量白蛋白尿和早期肾病的减缓有益处。
{"title":"Effects of angiotensin II receptor blockers on diabetic nephropathy.","authors":"Rigas Kalaitzidis,&nbsp;George L Bakris","doi":"10.1097/01.hjh.0000357904.71080.7d","DOIUrl":"https://doi.org/10.1097/01.hjh.0000357904.71080.7d","url":null,"abstract":"<p><p>Impaired kidney function increases the risk of cardiovascular morbidity and mortality. Coexistence of hypertension and type 2 diabetes increases the risk of kidney damage, hypertension being an independent risk factor for kidney disease progression. Angiotensin II, through its inflammatory, proliferative, and thrombotic effects, adversely affects renal perfusion and increases oxidative stress, thus playing a pivotal role in kidney disease progression. Angiotensin II receptor blockers (ARBs) and angiotensin-converting enzyme (ACE) inhibitors improve markers of kidney disease and slow kidney disease progression in diabetic and nondiabetic patients; this kidney protection may be in addition to their antihypertensive activity in those with advanced proteinuric nephropathy. Key beneficial effects of ARBs and ACE inhibitors throughout the kidney disease continuum are primarily explained by blood pressure lowering effects and partially by their direct blockade of angiotensin II. Recent studies have shown that telmisartan, an ARB with high lipophilicity and the longest half-life compared with other ARBs, provides benefits on markers of cardiovascular risk, that is, microalbuminuria and slowing of early-stage nephropathy.</p>","PeriodicalId":16074,"journal":{"name":"Journal of hypertension. Supplement : official journal of the International Society of Hypertension","volume":"27 5","pages":"S15-21"},"PeriodicalIF":0.0,"publicationDate":"2009-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.hjh.0000357904.71080.7d","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28294741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 31
Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor. 来自ONTARGET的临床证据:血管紧张素II受体阻滞剂和血管紧张素转换酶抑制剂的价值。
Peter Sleight

The Heart Outcomes Prevention Evaluation study established the angiotensin-converting enzyme inhibitor ramipril, versus placebo, for prevention of cardiovascular events in high-risk patients. The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) was later conducted in similar high-risk patients using multifactorial treatment to control hypertension, platelet aggregation, and dyslipidemia, while comparing ramipril, telmisartan, or their combination, without placebo. In ONTARGET, the first angiotensin II receptor blocker-based study to be performed in a broader population of patients without congestive heart failure and/or left ventricular hypertrophy/dysfunction, telmisartan provided cardiovascular protection that was noninferior to ramipril. However, greater blockade of the renin-angiotensin system, using their combination, was not superior to ramipril alone. Telmisartan was better tolerated than ramipril in this high-risk population: notably, the incidence of cough and angioedema was significantly lower with telmisartan alone. Thus, telmisartan provides comparable efficacy to ramipril with less adverse events, which may encourage patient compliance.

心脏预后预防评估研究确定血管紧张素转换酶抑制剂雷米普利与安慰剂相比,可预防高危患者的心血管事件。正在进行的替米沙坦单独和联合雷米沙坦全球终点试验(ONTARGET)随后在类似的高风险患者中进行,使用多因素治疗来控制高血压、血小板聚集和血脂异常,同时比较雷米沙坦、替米沙坦或它们的联合治疗,不使用安慰剂。在ONTARGET中,第一个基于血管紧张素II受体阻滞剂的研究,在没有充血性心力衰竭和/或左心室肥厚/功能障碍的患者中进行,替米沙坦提供的心血管保护不逊于雷米普利。然而,更大的阻断肾素-血管紧张素系统,使用他们的联合,并不优于雷米普利单独。在这一高危人群中,替米沙坦的耐受性优于雷米普利:值得注意的是,单独使用替米沙坦时咳嗽和血管性水肿的发生率显著降低。因此,替米沙坦提供与雷米普利相当的疗效,不良事件较少,这可能会鼓励患者依从性。
{"title":"Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor.","authors":"Peter Sleight","doi":"10.1097/01.hjh.0000357905.78704.9a","DOIUrl":"https://doi.org/10.1097/01.hjh.0000357905.78704.9a","url":null,"abstract":"<p><p>The Heart Outcomes Prevention Evaluation study established the angiotensin-converting enzyme inhibitor ramipril, versus placebo, for prevention of cardiovascular events in high-risk patients. The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) was later conducted in similar high-risk patients using multifactorial treatment to control hypertension, platelet aggregation, and dyslipidemia, while comparing ramipril, telmisartan, or their combination, without placebo. In ONTARGET, the first angiotensin II receptor blocker-based study to be performed in a broader population of patients without congestive heart failure and/or left ventricular hypertrophy/dysfunction, telmisartan provided cardiovascular protection that was noninferior to ramipril. However, greater blockade of the renin-angiotensin system, using their combination, was not superior to ramipril alone. Telmisartan was better tolerated than ramipril in this high-risk population: notably, the incidence of cough and angioedema was significantly lower with telmisartan alone. Thus, telmisartan provides comparable efficacy to ramipril with less adverse events, which may encourage patient compliance.</p>","PeriodicalId":16074,"journal":{"name":"Journal of hypertension. Supplement : official journal of the International Society of Hypertension","volume":"27 5","pages":"S23-9"},"PeriodicalIF":0.0,"publicationDate":"2009-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.hjh.0000357905.78704.9a","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28294742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 15
Defining blood pressure goals: is it enough to manage total cardiovascular risk? 确定血压目标:是否足以控制心血管总风险?
Giuseppe Mancia

It is well established that lowering blood pressure (BP) in patients with hypertension is associated with cardiovascular protection. Therefore, BP goals have been defined by international hypertension guidelines (<140/90 mmHg; <130/80 mmHg for patients with type 2 diabetes). However, the relationship of BP with prognosis is complex, and controlling office BP may not be enough to optimally manage total cardiovascular risk. It is becoming clear that out-of-office BP measurements have important prognostic value. In the observational Pressioni Arteriose Monitorate E Loro Associazioni study, the risk of cardiovascular death over 11 years was progressively higher with 10-mmHg increases in office, home, or ambulatory BPs. Smooth control of 24-h BP may be of even greater importance, as the early morning BP surge, nighttime BP, and BP variability are associated with significant risk. A further consideration in managing total cardiovascular risk is the need for multiple antihypertensive agents to control BP.

众所周知,降低高血压患者的血压与心血管保护有关。因此,国际高血压指南(
{"title":"Defining blood pressure goals: is it enough to manage total cardiovascular risk?","authors":"Giuseppe Mancia","doi":"10.1097/01.hjh.0000357902.93951.3a","DOIUrl":"https://doi.org/10.1097/01.hjh.0000357902.93951.3a","url":null,"abstract":"<p><p>It is well established that lowering blood pressure (BP) in patients with hypertension is associated with cardiovascular protection. Therefore, BP goals have been defined by international hypertension guidelines (<140/90 mmHg; <130/80 mmHg for patients with type 2 diabetes). However, the relationship of BP with prognosis is complex, and controlling office BP may not be enough to optimally manage total cardiovascular risk. It is becoming clear that out-of-office BP measurements have important prognostic value. In the observational Pressioni Arteriose Monitorate E Loro Associazioni study, the risk of cardiovascular death over 11 years was progressively higher with 10-mmHg increases in office, home, or ambulatory BPs. Smooth control of 24-h BP may be of even greater importance, as the early morning BP surge, nighttime BP, and BP variability are associated with significant risk. A further consideration in managing total cardiovascular risk is the need for multiple antihypertensive agents to control BP.</p>","PeriodicalId":16074,"journal":{"name":"Journal of hypertension. Supplement : official journal of the International Society of Hypertension","volume":"27 5","pages":"S3-8"},"PeriodicalIF":0.0,"publicationDate":"2009-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.hjh.0000357902.93951.3a","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28294743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
Cardiovascular protection: a breakthrough for high-risk patients? 心血管保护:高危患者的突破?
Roberto Ferrari

Angiotensin II has diverse effects on cardiovascular structure and function, and hence drugs that inhibit the formation or activity of this peptide have attained a central position in the prevention of morbidity and mortality from cardiovascular causes. The recent ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) has shown that, in patients with vascular disease or patients with diabetes who were at high risk of cardiovascular events, the angiotensin II receptor blocker telmisartan is noninferior to the angiotensin-converting enzyme inhibitor ramipril in preventing such events, despite the ONTARGET patients receiving better background preventive therapy than those enrolled in the earlier Heart Outcomes Prevention Evaluation (HOPE) study. In addition, telmisartan offers superior tolerability to that of ramipril. Moreover, the finding in this study that combination therapy with telmisartan and ramipril produced no further reduction in cardiovascular events than either drug alone, despite producing greater reductions in blood pressure, highlights the potential importance of endothelial effects of renin-angiotensin system blockade in cardiovascular protection.

血管紧张素II对心血管结构和功能有多种影响,因此抑制这种肽的形成或活性的药物在预防心血管疾病的发病率和死亡率方面处于中心地位。最近正在进行的替米沙坦单独和联合雷米普利全球终点试验(ONTARGET)表明,在心血管事件高风险的血管疾病患者或糖尿病患者中,血管紧张素II受体阻滞剂替米沙坦在预防此类事件方面不逊于血管紧张素转换酶抑制剂雷米普利。尽管ONTARGET患者比早期心脏结局预防评估(HOPE)研究的患者接受了更好的背景预防治疗。此外,替米沙坦的耐受性优于雷米普利。此外,本研究发现,替米沙坦和雷米普利联合治疗没有比单独使用任何一种药物进一步减少心血管事件,尽管可以产生更大的血压降低,这突出了肾素-血管紧张素系统阻断在心血管保护中的内皮效应的潜在重要性。
{"title":"Cardiovascular protection: a breakthrough for high-risk patients?","authors":"Roberto Ferrari","doi":"10.1097/01.hjh.0000357907.68402.99","DOIUrl":"https://doi.org/10.1097/01.hjh.0000357907.68402.99","url":null,"abstract":"<p><p>Angiotensin II has diverse effects on cardiovascular structure and function, and hence drugs that inhibit the formation or activity of this peptide have attained a central position in the prevention of morbidity and mortality from cardiovascular causes. The recent ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) has shown that, in patients with vascular disease or patients with diabetes who were at high risk of cardiovascular events, the angiotensin II receptor blocker telmisartan is noninferior to the angiotensin-converting enzyme inhibitor ramipril in preventing such events, despite the ONTARGET patients receiving better background preventive therapy than those enrolled in the earlier Heart Outcomes Prevention Evaluation (HOPE) study. In addition, telmisartan offers superior tolerability to that of ramipril. Moreover, the finding in this study that combination therapy with telmisartan and ramipril produced no further reduction in cardiovascular events than either drug alone, despite producing greater reductions in blood pressure, highlights the potential importance of endothelial effects of renin-angiotensin system blockade in cardiovascular protection.</p>","PeriodicalId":16074,"journal":{"name":"Journal of hypertension. Supplement : official journal of the International Society of Hypertension","volume":"27 5","pages":"S37-40"},"PeriodicalIF":0.0,"publicationDate":"2009-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.hjh.0000357907.68402.99","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28294745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Introduction: Reducing cardiovascular risk: ONTARGET--a new standard in cardiovascular protection. 前言:降低心血管风险:ONTARGET——心血管保护的新标准。
Giuseppe Mancia, Thomas Unger, Alberto Zanchetti
The papers that comprise this supplement were presented at two satellite symposia held in Berlin on the 17 and 18 June 2008 at the joint congress for the 18 Scientific Meeting of the European Society of Hypertension and the 22nd Scientific Meeting of the International Society of Hypertension. The two symposia were sponsored by Boehringer Ingelheim and were entitled ‘Reducing Cardiovascular Risk: New Insights From ONTARGET, and ‘ONTARGET: New Standard in Cardio & Vascular Protection’. The aim of the lectures in these symposia was to provide a wider perspective of the landmark ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) Programme.
{"title":"Introduction: Reducing cardiovascular risk: ONTARGET--a new standard in cardiovascular protection.","authors":"Giuseppe Mancia,&nbsp;Thomas Unger,&nbsp;Alberto Zanchetti","doi":"10.1097/01.hjh.0000357901.86327.d8","DOIUrl":"https://doi.org/10.1097/01.hjh.0000357901.86327.d8","url":null,"abstract":"The papers that comprise this supplement were presented at two satellite symposia held in Berlin on the 17 and 18 June 2008 at the joint congress for the 18 Scientific Meeting of the European Society of Hypertension and the 22nd Scientific Meeting of the International Society of Hypertension. The two symposia were sponsored by Boehringer Ingelheim and were entitled ‘Reducing Cardiovascular Risk: New Insights From ONTARGET, and ‘ONTARGET: New Standard in Cardio & Vascular Protection’. The aim of the lectures in these symposia was to provide a wider perspective of the landmark ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) Programme.","PeriodicalId":16074,"journal":{"name":"Journal of hypertension. Supplement : official journal of the International Society of Hypertension","volume":"27 5","pages":"S1"},"PeriodicalIF":0.0,"publicationDate":"2009-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.hjh.0000357901.86327.d8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28294740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Preventing stroke: the PRoFESS, ONTARGET, and TRANSCEND trial programs. 预防中风:PRoFESS、ONTARGET和TRANSCEND试验项目。
Hans-Christoph Diener

Renin-angiotensin system blockers have been shown to reduce stroke risk, partly independent of their blood pressure-lowering effect. The PReventiOn regimen For Effectively avoiding Second Strokes (PRoFESS) trial, ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) and Telmisartan Randomized AssessmeNt Study in aCE-iNtolerant subjects with cardiovascular Disease (TRANSCEND) recently showed potential benefits of the angiotensin II receptor blocker, telmisartan, in reducing secondary strokes. In PRoFESS, 20 332 ischemic stroke patients were randomized to telmisartan 80 mg versus placebo and to two antiplatelets in a 2 x 2 factorial design. After a mean exposure of 2 years, telmisartan showed a nonsignificant lower rate of recurrent stroke versus placebo [880 versus 934; hazard ratio 0.95; 95% confidence interval (CI) 0.86-1.04]. In a post-hoc analysis, from 6 months, telmisartan significantly reduced the number of strokes versus placebo (533 versus 608; hazard ratio 0.88; 95% CI 0.78-0.99; P = 0.042). In the stroke subgroup of ONTARGET, telmisartan 80 mg showed a trend toward reducing recurrent stroke versus ramipril 10 mg (hazard ratio 0.91; 95% CI 0.79-1.05). In the TRANSCEND study, 5926 patients who were intolerant to angiotensin-converting enzyme inhibitors were treated with 80 mg telmisartan or placebo. In a combined analysis of PRoFESS and TRANSCEND, the incidence of the composite of stroke, myocardial infarction, or vascular death was 12.8% for telmisartan versus 13.8% for placebo (hazard ratio 0.91; 95% CI 0.85-0.98; P = 0.013).

肾素-血管紧张素系统阻滞剂已被证明可以降低中风风险,部分独立于它们的降血压效果。有效避免二次卒中的预防方案(PRoFESS)试验,正在进行的替米沙坦单独和联合雷米普利全球终点试验(ONTARGET)和替米沙坦随机评估研究(TRANSCEND)在ace不耐受的心血管疾病患者中最近显示血管紧张素II受体阻滞剂替米沙坦在减少继发性卒中方面的潜在益处。在PRoFESS中,20332名缺血性卒中患者在2 × 2因子设计中随机接受替米沙坦80mg vs安慰剂和两种抗血小板药物治疗。平均暴露2年后,替米沙坦与安慰剂相比,卒中复发率没有显著降低[880比934;风险比0.95;95%置信区间(CI) 0.86-1.04]。在一项事后分析中,从6个月开始,替米沙坦与安慰剂相比显著减少了中风的数量(533 vs 608;风险比0.88;95% ci 0.78-0.99;P = 0.042)。在ONTARGET的卒中亚组中,替米沙坦80mg与雷米普利10mg相比显示出减少卒中复发的趋势(风险比0.91;95% ci 0.79-1.05)。TRANSCEND研究中,5926例对血管紧张素转换酶抑制剂不耐受的患者接受80mg替米沙坦或安慰剂治疗。在PRoFESS和TRANSCEND的联合分析中,替米沙坦组卒中、心肌梗死或血管性死亡的复合发生率为12.8%,而安慰剂组为13.8%(风险比0.91;95% ci 0.85-0.98;P = 0.013)。
{"title":"Preventing stroke: the PRoFESS, ONTARGET, and TRANSCEND trial programs.","authors":"Hans-Christoph Diener","doi":"10.1097/01.hjh.0000357906.60778.7f","DOIUrl":"https://doi.org/10.1097/01.hjh.0000357906.60778.7f","url":null,"abstract":"<p><p>Renin-angiotensin system blockers have been shown to reduce stroke risk, partly independent of their blood pressure-lowering effect. The PReventiOn regimen For Effectively avoiding Second Strokes (PRoFESS) trial, ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) and Telmisartan Randomized AssessmeNt Study in aCE-iNtolerant subjects with cardiovascular Disease (TRANSCEND) recently showed potential benefits of the angiotensin II receptor blocker, telmisartan, in reducing secondary strokes. In PRoFESS, 20 332 ischemic stroke patients were randomized to telmisartan 80 mg versus placebo and to two antiplatelets in a 2 x 2 factorial design. After a mean exposure of 2 years, telmisartan showed a nonsignificant lower rate of recurrent stroke versus placebo [880 versus 934; hazard ratio 0.95; 95% confidence interval (CI) 0.86-1.04]. In a post-hoc analysis, from 6 months, telmisartan significantly reduced the number of strokes versus placebo (533 versus 608; hazard ratio 0.88; 95% CI 0.78-0.99; P = 0.042). In the stroke subgroup of ONTARGET, telmisartan 80 mg showed a trend toward reducing recurrent stroke versus ramipril 10 mg (hazard ratio 0.91; 95% CI 0.79-1.05). In the TRANSCEND study, 5926 patients who were intolerant to angiotensin-converting enzyme inhibitors were treated with 80 mg telmisartan or placebo. In a combined analysis of PRoFESS and TRANSCEND, the incidence of the composite of stroke, myocardial infarction, or vascular death was 12.8% for telmisartan versus 13.8% for placebo (hazard ratio 0.91; 95% CI 0.85-0.98; P = 0.013).</p>","PeriodicalId":16074,"journal":{"name":"Journal of hypertension. Supplement : official journal of the International Society of Hypertension","volume":"27 5","pages":"S31-6"},"PeriodicalIF":0.0,"publicationDate":"2009-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.hjh.0000357906.60778.7f","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28294744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 24
Dual blockade versus single blockade of the renin-angiotensin system in the light of ONTARGET. 根据ONTARGET,肾素-血管紧张素系统的双重阻断与单一阻断。
Isabella Sudano, Georg Noll

Angiotensin II plays an important role in the cardiovascular continuum starting with risk factors and progressing to atherosclerosis, target organ damage, and ultimately to heart failure, stroke, or death. Inhibiting the renin-angiotensin-aldosterone system (RAAS) represents a cornerstone for the treatment of hypertension and heart failure. In patients with heart failure, the single RAAS blockade with angiotensin-converting enzyme (ACE) inhibitors have been shown to reduce morbidity and mortality, increase life expectancy, and preserve the renal function. AT1 receptor blockers (ARBs) are equally effective in reducing mortality and morbidity in patients with impaired left ventricular function. The combination of ACE inhibitors with ARBs leads to an additive blood pressure lowering effect, better reduction in proteinuria, and to additive benefits in heart failure and left ventricular hypertrophy. But combination therapy is also associated with more side effects. Further investigations evaluating the effect of dual RAAS blockade on fatal and nonfatal cardiovascular events are needed.

血管紧张素II在心血管连续过程中起着重要作用,从危险因素开始,发展到动脉粥样硬化、靶器官损伤,最终到心力衰竭、中风或死亡。抑制肾素-血管紧张素-醛固酮系统(RAAS)是治疗高血压和心力衰竭的基石。在心力衰竭患者中,血管紧张素转换酶(ACE)抑制剂的单一RAAS阻断已被证明可以降低发病率和死亡率,增加预期寿命,并保持肾功能。AT1受体阻滞剂(ARBs)在降低左心室功能受损患者的死亡率和发病率方面同样有效。血管紧张素转换酶抑制剂与arb联合使用可导致附加的降血压效果,更好地减少蛋白尿,并对心力衰竭和左心室肥厚有附加的益处。但是联合治疗也有更多的副作用。需要进一步的研究来评估双重RAAS阻断对致死性和非致死性心血管事件的影响。
{"title":"Dual blockade versus single blockade of the renin-angiotensin system in the light of ONTARGET.","authors":"Isabella Sudano,&nbsp;Georg Noll","doi":"10.1097/01.hjh.0000354513.52203.a4","DOIUrl":"https://doi.org/10.1097/01.hjh.0000354513.52203.a4","url":null,"abstract":"<p><p>Angiotensin II plays an important role in the cardiovascular continuum starting with risk factors and progressing to atherosclerosis, target organ damage, and ultimately to heart failure, stroke, or death. Inhibiting the renin-angiotensin-aldosterone system (RAAS) represents a cornerstone for the treatment of hypertension and heart failure. In patients with heart failure, the single RAAS blockade with angiotensin-converting enzyme (ACE) inhibitors have been shown to reduce morbidity and mortality, increase life expectancy, and preserve the renal function. AT1 receptor blockers (ARBs) are equally effective in reducing mortality and morbidity in patients with impaired left ventricular function. The combination of ACE inhibitors with ARBs leads to an additive blood pressure lowering effect, better reduction in proteinuria, and to additive benefits in heart failure and left ventricular hypertrophy. But combination therapy is also associated with more side effects. Further investigations evaluating the effect of dual RAAS blockade on fatal and nonfatal cardiovascular events are needed.</p>","PeriodicalId":16074,"journal":{"name":"Journal of hypertension. Supplement : official journal of the International Society of Hypertension","volume":"27 2","pages":"S11-4"},"PeriodicalIF":0.0,"publicationDate":"2009-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.hjh.0000354513.52203.a4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28216851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Practical aspects of treatment discontinuation and adherence. 停止治疗和坚持治疗的实际方面。
Gianfranco Parati, Grzegorz Bilo

Hypertension control in populations, although improving, remains far from satisfactory, even though effective and inexpensive therapies are available. Among many factors responsible for this situation, poor adherence to treatment appears to be particularly important. Unfortunately, even if its causes have been quite well defined, this problem is still far from being solved in clinical practice. The present paper discusses the key issues related to treatment adherence, and discontinuation in hypertension, in the light of recent evidence coming from the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) and Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease trial (TRANSCEND).

人群中的高血压控制虽然有所改善,但仍远不能令人满意,即使有有效和廉价的治疗方法。在造成这种情况的许多因素中,治疗依从性差似乎尤为重要。不幸的是,即使它的原因已经相当明确,这个问题在临床实践中仍远未得到解决。本文根据正在进行的替米沙坦单独和联合雷米普利全球终点试验(ONTARGET)和替米沙坦随机评估研究在ACE不耐受的心血管疾病患者试验(TRANSCEND)的最新证据,讨论了与高血压患者治疗依从性和停药相关的关键问题。
{"title":"Practical aspects of treatment discontinuation and adherence.","authors":"Gianfranco Parati,&nbsp;Grzegorz Bilo","doi":"10.1097/01.hjh.0000354515.36956.67","DOIUrl":"https://doi.org/10.1097/01.hjh.0000354515.36956.67","url":null,"abstract":"<p><p>Hypertension control in populations, although improving, remains far from satisfactory, even though effective and inexpensive therapies are available. Among many factors responsible for this situation, poor adherence to treatment appears to be particularly important. Unfortunately, even if its causes have been quite well defined, this problem is still far from being solved in clinical practice. The present paper discusses the key issues related to treatment adherence, and discontinuation in hypertension, in the light of recent evidence coming from the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) and Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease trial (TRANSCEND).</p>","PeriodicalId":16074,"journal":{"name":"Journal of hypertension. Supplement : official journal of the International Society of Hypertension","volume":"27 2","pages":"S18-21"},"PeriodicalIF":0.0,"publicationDate":"2009-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.hjh.0000354515.36956.67","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28216853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Arterial hypertension greatly contributes to the development and evolution of cardiovascular and renal diseases. Editorial. 动脉高血压对心血管和肾脏疾病的发展和演变有很大的促进作用。社论。
Luis M Ruilope
{"title":"Arterial hypertension greatly contributes to the development and evolution of cardiovascular and renal diseases. Editorial.","authors":"Luis M Ruilope","doi":"10.1097/01.hjh.0000356765.78765.7f","DOIUrl":"https://doi.org/10.1097/01.hjh.0000356765.78765.7f","url":null,"abstract":"","PeriodicalId":16074,"journal":{"name":"Journal of hypertension. Supplement : official journal of the International Society of Hypertension","volume":"27 3","pages":"S1"},"PeriodicalIF":0.0,"publicationDate":"2009-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.hjh.0000356765.78765.7f","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28228245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Journal of hypertension. Supplement : official journal of the International Society of Hypertension
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1